60 Degrees Pharmaceuticals (SXTP) Profit After Tax (2022 - 2026)

60 Degrees Pharmaceuticals (SXTP) has reported Profit After Tax for 5 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 11.34% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$7.6 million (up 26.12% YoY), while the FY2025 annual figure was -$7.4 million, up 7.42% from the prior year.
• Profit After Tax retreated to -$2.1 million in Q1 2026 per SXTP's latest filing, from -$1.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at $4.6 million in Q4 2022 and bottomed at -$4.2 million in Q2 2024.
• Historically, Profit After Tax has averaged -$1.3 million across 5 years, with a median of -$2.1 million in 2023.
• Annual changes were most pronounced in 2023 — Profit After Tax soared 388.34% — and 2025, when it slumped 538.64%.
• 60 Degrees Pharmaceuticals' Profit After Tax stood at $4.6 million in 2022, then tumbled by 144.57% to -$2.1 million in 2023, then increased by 0.24% to -$2.0 million in 2024, then rose by 29.79% to -$1.4 million in 2025, then tumbled by 45.3% to -$2.1 million in 2026.
• Business Quant data shows SXTP's Profit After Tax at -$2.1 million in Q1 2026, -$1.4 million in Q4 2025, and -$2.3 million in Q3 2025.